CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana Biotechnology announced the publication of groundbreaking preclinical data in the ...

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Intellia's third-quarter 2025 financial results demonstrated clear operational strength. The company reported revenue of $13.78 million, representing a substantial year-over-year increase of 51.6%.

Earlier in the week, ARK purchased 10,353 shares of CRISPR on Wednesday, valued at $584,530, and 43,333 shares on Tuesday, totaling $2,509,414. This consistent buying pattern suggests a strong ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

Gene editing has rapidly evolved into a transformative class of technologies that allow scientists to precisely insert, ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. CRISPR Therapeutics CRSP now clears that threshold, with a jump from 79 to 82 Tuesday. Please watch the video ...